Tiling array-CGH for the assessment of genomic similarities among synchronous unilateral and bilateral invasive breast cancer tumor pairs

BMC Clinical Pathology

Volumn 8, Issue 1, 2008, Pages

  Brommesson, Sara ^a   Jönsson, Göran ^a   Strand, Carina ^a   Grabau, Dorthe ^a   Malmström, Per ^a   Ringnér, Markus ^a   Fernö, Mårten ^a   Hedenfalk, Ingrid ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CHROMOSOME ABERRATION; CHROMOSOME PAIRING; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; GENE CLUSTER; GENOME ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MICROARRAY ANALYSIS; MOLECULAR CLONING; PRIMARY TUMOR;

EID: 47649128110     PISSN: 14726890     EISSN: 14726890     Source Type: Journal    
DOI: 10.1186/1472-6890-8-6     Document Type: Article

References (38)

1. Bilateral primary breast cancer: a prospective study of disease incidence. MA Chaudary RR Millis EO Hoskins M Halder RD Bulbrook J Cuzick JL Hayward, Br J Surg 1984 71 9 711 714 10.1002/bjs.1800710924 6478165
2. Genetic implications of bilateral breast cancer: a population based cohort study. M Hartman K Czene M Reilly J Bergh P Lagiou D Trichopoulos HO Adami P Hall, Lancet Oncol 2005 6 6 377 382 10.1016/S1470-2045(05)70174-1 15925815
3. Bilateral carcinoma of the breast: frequency and mortality. CB Mueller F Ames, Can J Surg 1978 21 5 459 465 719574
4. Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. DE Heron LT Komarnicky T Hyslop GF Schwartz CM Mansfield, Cancer 2000 88 12 2739 2750 10.1002/1097-0142(20000615) 88:12〈2739::AID-CNCR12〉3.0.CO;2-J 10870056
5. Synchronous, bilateral breast cancer: prognostic value and incidence. JJ Jobsen J van der Palen F Ong JH Meerwaldt, Breast 2003 12 2 83 88 10.1016/S0960-9776(02)00278-3 14659335
6. Clinical and histological predictors of contralateral breast cancer. J Kollias IO Ellis CW Elston RW Blamey, Eur J Surg Oncol 1999 25 6 584 589 10.1053/ejso.1999.0711 10556004
7. What is new in our understanding of multifocal breast cancer. PJ Dawson, Pathol Res Pract 1993 189 1 111 116 8516211
8. Discrimination between multicentric and multifocal breast carcinoma by cytogenetic investigation of macroscopically distinct ipsilateral lesions. MR Teixeira N Pandis G Bardi JA Andersen PJ Bohler H Qvist S Heim, Genes Chromosomes Cancer 1997 18 3 170 174 10.1002/(SICI)1098-2264(199703)18: 3〈170::AID-GCC3〉3.0.CO;2-Z 9071569
9. The use of molecular assays to establish definitively the clonality of ipsilateral breast tumor recurrences and patterns of in-breast failure in patients with early-stage breast cancer treated with breast-conserving therapy. FA Vicini JV Antonucci N Goldstein M Wallace L Kestin D Krauss J Kunzmann S Gilbert S Schell, Cancer 2007 109 7 1264 1272 10.1002/cncr.22529 17372920
10. Concordance of allelic imbalance profiles in synchronous and metachronous bilateral breast carcinomas. EN Imyanitov EN Suspitsin MY Grigoriev AV Togo ES Kuligina EV Belogubova KM Pozharisski EA Turkevich C Rodriquez CJ Cornelisse KP Hanson C Theillet, Int J Cancer 2002 100 5 557 564 10.1002/ijc.10530 12124805
11. Discrimination between multicentric and multifocal carcinomas of the breast through clonal analysis. S Noguchi T Aihara H Koyama K Motomura H Inaji S Imaoka, Cancer 1994 74 3 872 877 10.1002/1097-0142(19940801)74:3〈872::AID- CNCR2820740313〉3.0.CO;2-P 8039114
12. Differentiation of primary and secondary breast cancer with clonal analysis. S Noguchi K Motomura H Inaji S Imaoka H Koyama, Surgery 1994 115 4 458 462 7909387
13. Clonal analysis of bilateral breast cancer. A Shibata YC Tsai MF Press BE Henderson PA Jones RK Ross, Clin Cancer Res 1996 2 4 743 748 9816225
14. Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer. E Janschek D Kandioler-Eckersberger C Ludwig S Kappel B Wolf S Taucher M Rudas M Gnant R Jakesz, Breast Cancer Res Treat 2001 67 1 1 8 10.1023/A:1010661514306 11518461
15. Protein accumulation and gene mutation of p53 in bilateral breast cancer. South-East Sweden Breast Cancer Group. M Stenmark-Askmalm M Gentile S Wingren O Stahl, Acta Oncol 2001 40 1 56 62 10.1080/028418601750071064 11321662
16. Assessment of clonal relationships in ipsilateral and bilateral multiple breast carcinomas by comparative genomic hybridisation and hierarchical clustering analysis. MR Teixeira FR Ribeiro L Torres N Pandis JA Andersen RA Lothe S Heim, Br J Cancer 2004 91 4 775 782 15266323
17. Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases. L Torres FR Ribeiro N Pandis JA Andersen S Heim MR Teixeira, Breast Cancer Res Treat 2007 102 2 143 155 10.1007/s10549-006-9317-6 16906480
18. Genomic microarrays in human genetic disease and cancer. DG Albertson D Pinkel, Hum Mol Genet 2003 12 Suppl 2 R145 52 10.1093/hmg/ddg261
19. Genomic alterations in sporadic synchronous primary breast cancer using array and metaphase comparative genomic hybridization. AA Ghazani N Arneson K Warren M Pintilie J Bayani JA Squire SJ Done, Neoplasia 2007 9 6 511 520 17603634 10.1593/neo.07301
20. Clinical application of array-based comparative genomic hybridization to define the relationship between multiple synchronous tumors. CV Wa S DeVries YY Chen FM Waldman ES Hwang, Mod Pathol 2005 18 4 591 597 10.1038/modpathol.3800332 15696129
21. Assessment of histological grade. CW Elston IO Ellis, Systemic Pathology The Breast London, Churchill Livingston, Elston CW, Ellis IO, 3 1998
22. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group. M Ferno O Stal B Baldetorp T Hatschek AC Kallstrom P Malmstrom B Nordenskjold S Ryden, Breast Cancer Res Treat 2000 59 1 69 76 10.1023/A:1006332423620 10752681
23. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. L Ryden PE Jonsson G Chebil M Dufmats M Ferno K Jirstrom AC Kallstrom G Landberg O Stal S Thorstenson B Nordenskjold, Eur J Cancer 2005 41 2 256 264 10.1016/j.ejca.2004. 06.030 15661551
24. Improved DNA flow cytometric, DNA ploidy, and S-phase reproducibility between 15 laboratories in analysis of breast cancer using generalized guidelines. B Baldetorp PO Bendahl M Ferno O Stal, Cytometry A 2003 56 1 1 7 10.1002/cyto.a.10083 14566933
25. Genomic Rearrays Mapping Data - Resources. http://bacpac.chori.org/ genomicRearrays.php
26. High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. G Jonsson J Staaf E Olsson M Heidenblad J Vallon-Christersson K Osoegawa P de Jong S Oredsson M Ringner M Hoglund A Borg, Genes Chromosomes Cancer 2007 46 6 543 558 10.1002/gcc.20438 17334996
27. Genomic profiling of malignant melanoma using tiling-resolution arrayCGH. G Jonsson C Dahl J Staaf T Sandberg PO Bendahl M Ringner P Guldberg A Borg, Oncogene 2007 26 32 4738 4748 10.1038/sj.onc.1210252 17260012
28. Assembly of microarrays for genome-wide measurement of DNA copy number. AM Snijders N Nowak R Segraves S Blackwood N Brown J Conroy G Hamilton AK Hindle B Huey K Kimura S Law K Myambo J Palmer B Ylstra JP Yue JW Gray AN Jain D Pinkel DG Albertson, Nat Genet 2001 29 3 263 264 10.1038/ng754 11687795
29. BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data. LH Saal C Troein J Vallon-Christersson S Gruvberger A Borg C Peterson, Genome Biol 2002 3 8 SOFTWARE0003 12186655 10.1186/gb-2002-3-8-software0003
30. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. YH Yang S Dudoit P Luu DM Lin V Peng J Ngai TP Speed, Nucleic Acids Res 2002 30 4 e15 11842121 10.1093/nar/30.4.e15
31. CGH-Plotter: MATLAB toolbox for CGH-data analysis. R Autio S Hautaniemi P Kauraniemi O Yli-Harja J Astola M Wolf A Kallioniemi, Bioinformatics 2003 19 13 1714 1715 10.1093/bioinformatics/btg230 15593402
32. Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. G Jonsson TL Naylor J Vallon-Christersson J Staaf J Huang MR Ward JD Greshock L Luts H Olsson N Rahman M Stratton M Ringner A Borg BL Weber, Cancer Res 2005 65 17 7612 7621 16140926
33. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. K Chin S DeVries J Fridlyand PT Spellman R Roydasgupta WL Kuo A Lapuk RM Neve Z Qian T Ryder F Chen H Feiler T Tokuyasu C Kingsley S Dairkee Z Meng K Chew D Pinkel A Jain BM Ljung L Esserman DG Albertson FM Waldman JW Gray, Cancer Cell 2006 10 6 529 541 10.1016/j.ccr.2006.10.009 17157792
34. Cytogenetic analysis of multifocal breast carcinomas: detection of karyotypically unrelated clones as well as clonal similarities between tumour foci. MR Teixeira N Pandis G Bardi JA Andersen N Mandahl F Mitelman S Heim, Br J Cancer 1994 70 5 922 927 7947098
35. Multicentric mammary carcinoma: evidence of monoclonal proliferation. LP Middleton G Vlastos NQ Mirza S Eva AA Sahin, Cancer 2002 94 7 1910 1916 10.1002/cncr.10452 11932891
36. Mechanisms of multifocal breast cancer: an immunocytochemical study. PJ Dawson PA Baekey RA Clark, Hum Pathol 1995 26 9 965 969 10.1016/0046-8177(95) 90085-3 7672796
37. Quantitative DNA fingerprinting may distinguish new primary breast cancer from disease recurrence. BL Schlechter Q Yang PS Larson A Golubeva RA Blanchard A de las Morenas CL Rosenberg, J Clin Oncol 2004 22 10 1830 1838 10.1200/JCO.2004.05.123 15143075
38. High-resolution mapping of DNA breakpoints to define true recurrences among ipsilateral breast cancers. MA Bollet N Servant P Neuvial C Decraene I Lebigot JP Meyniel Y De Rycke A Savignoni G Rigaill P Hupe A Fourquet B Sigal-Zafrani E Barillot JP Thiery, J Natl Cancer Inst 2008 100 1 48 58 18159071